REG - Redx Pharma plc - Appointment of Non-Executive Director

Redx PharmaAnnouncement

27/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220127:nRSa7756Za&default-theme=true

RNS Number : 7756Z  Redx Pharma plc  27 January 2022

REDX PHARMA PLC

("Redx" or "the Company")

 

Appointment of Non-Executive Director

 

Dr Rob Scott brings extensive clinical development and regulatory experience
to Board

 

Alderley Park, UK, 27 January 2022 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, highly targeted therapeutics for the treatment of cancer and
fibrotic disease, is pleased to announce the appointment of Dr Rob Scott as a
Non-Executive Director with immediate effect.

Dr Scott brings extensive clinical development and regulatory experience to
the Board, having held senior leadership positions in global pharma for over
thirty years. Most recently, Dr Scott retired as Chief Medical Officer at
AbbVie, where he oversaw 14 major regulatory approvals including Venclexta,
Orilissa, Skyrizi and Rinvoq. Recent prior experience includes the roles of
Vice President of Global Development at Amgen and Industry Representative on
the US Food and Drug Administration Cardiac and Renal Drug Advisory Committee.
Dr Scott is currently on the boards of ArisGlobal, Confo Therapeutics,
Draupnir Bio, Windtree Therapeutics and Oncospherix as well as several
scientific advisory boards. Dr Scott is a Zimbabwean born physician and a
graduate of the University of Cape Town.

Dr Jane Griffiths, Chair of the Board of Redx, commented: "We are excited to
welcome Rob onto the Redx Board. As we build our portfolio of clinical stage
assets, Rob will bring a clinical development and regulatory perspective to
help shape our programmes, particularly in the US where he has been based for
almost 30 years. The Board and I look forward to working with Rob to ensure
that we continue to grow Redx into a successful biotech company focused on the
treatment of cancer and fibrotic disease."

 

Dr Rob Scott commented "I am delighted to be joining the Redx Board,
especially at a time where there is real momentum with the Company's cancer
and fibrosis assets in the clinic. I look forward to working with the Board as
Redx continues to progress its exciting drug candidates through the clinical
development process."

 

Following Dr Scott's appointment, the Board will be comprised of eight
directors, five of whom, including the Chair, are independent Non-Executive
Directors (Dr Jane Griffiths, Peter Presland, Dr Bernhard Kirschbaum, Sarah
Gordon Wild and Dr Rob Scott), two shareholder representative Non-Executive
Directors (Natalie Berner and Dr Thomas Burt) and Redx's Chief Executive
Officer, Lisa Anson.

 

 

Additional information:

 

The following information is being disclosed pursuant to Rule 17 and paragraph
(g) of Schedule 2 of the AIM Rules for Companies:

 

Full name and age: Robert Andrew Donald Scott, aged 68

Dr Scott does not hold any shares in the Company

Dr Scott holds or has previously held the following directorships:

 

 Current directorships and/or partnerships  Former directorships and/or partnerships (within the last five years):
 Windtree Therapeutics Inc                  Chicago Council on Science and Technology

 Confo Therapeutics NV                      TransCelerate BioPharma Inc

 ArisGlobal LLC                             Kanan Therapeutics Inc

 Draupnir Bio ApS

 Oncospherix

 

 

 

 For further information, please contact:

 Redx Pharma Plc                                 T: +44 (0)1625 469 918

 UK Headquarters

 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)     T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                  T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)      T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                  T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic diseases, aiming
initially to progress them to clinical proof of concept before evaluating
options for further development and potential value creation. Redx's lead
oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase
2 programme in November 2021. The Company's selective ROCK2 inhibitor product
candidate, RXC007, is in development for idiopathic pulmonary fibrosis and
commenced a Phase 1 clinical trial in June 2021. Initial results were reported
in October 2021, with full Phase 1 results expected in 2022.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK
inhibitor now in Phase 3 clinical development by Eli Lilly following its
acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting
fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which
AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has
forged collaborations with Jazz Pharmaceuticals.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABKABDBBKBKDB